Dame Emma Walmsley announced earlier this week she is stepping down as chief executive of GlaxoSmithKline — one of the biggest posts in the pharmaceutical industry. GSK is a stalwart of British business, employing more than 65,000 people. Since 2017, Walmsley has manned the ship in turbulent times, facing pressure to step down in 2021 by activist investor Elliott Management, and launched GSK’s consumer healthcare business Haleon. Luke Miels, who controversially swapped teams from AstraZeneca back in 2017, will replace Walmsley.
